HP518 Xinovaning maqsadli oqsil parchalanishiga qarshi dori kashfiyot platformasi tomonidan kashf etilgan va ishlab chiqilgan. U ba'zi o'ziga xos AR mutatsiyalari tufayli prostata saratonining dori qarshiligini engish imkoniyatiga ega.
Ximerik degradatorlar ikki funktsiyali kichik molekulalar bo'lib, ular yuqori quvvat va yuqori selektivlik bilan maqsadli oqsillarning parchalanishiga yordam beradi. Ushbu texnologiya giyohvand bo'lmagan maqsadlarga erishish va an'anaviy kichik molekula dori vositalarining dori-darmonlarga chidamliligi muammosini bartaraf etish imkoniyatiga ega.
“Bu dori kashfiyotidan klinik tadqiqotgacha bo‘lgan sa’y-harakatlarimizdagi muhim bosqichdir”, dedi Yuanvey Chen, PhD, Xinova prezidenti va bosh direktori. "Biz bundan juda xursandmiz va butun dunyo bo'ylab bemorlarga yangi davolash usullarini taqdim etishga intilamiz!"
Maqsadli protein degradatsiyasiga qarshi dori kashfiyot platformasi orqali Hinova oqsil parchalanish faolligini tezda tekshirishi va kimerik degradatorlarni samarali loyihalash va optimallashtirishni amalga oshirishi mumkin. Bundan tashqari, Xinova kimerik degradator birikmalarini kimyoviy ishlab chiqarishni nazorat qilishda katta tajribaga ega.
USHBU MAQOLADAN NIMA OLISH KERAK:
- Through the targeted protein degradation drug discovery platform, Hinova can screen protein degradation activity rapidly and accomplish efficient design and optimization of chimeric degraders.
- “This is a significant milestone in the progress of our efforts from drug discovery to the clinical study,”.
- This technology has the potential to target non-druggable targets and to overcome the drug resistance issue of traditional small molecule drugs.
